FPMI Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
FluoroPharma Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.0002 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 0% |
| 5 Year Change | -98.00% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
| FPMI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -1.1% | -0.3% |
| 1Y | n/a | -2.3% | 20.4% |
Return vs Industry: Insufficient data to determine how FPMI performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how FPMI performed against the US Market.
Price Volatility
| FPMI volatility | |
|---|---|
| FPMI Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 18.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FPMI's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine FPMI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | n/a | www.fluoropharma.com |
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with initial applications in the area of cardiology in the United States. Its product candidates include BFPET, an imaging agent that has completed a Phase I clinical trial in stress-testing for patients with presumptive or proven coronary artery disease (CAD); and CardioPET, a molecular imaging agent, which is in Phase IIa clinical trial to assess myocardial blood flow and metabolism in patients with CAD. The company has license agreements with Massachusetts General Hospital and Sinotau USA; and clinical research agreements with Pharmaceutical Product Development, LLC, as well as Cardiovascular Imaging Technologies.
FluoroPharma Medical, Inc. Fundamentals Summary
| FPMI fundamental statistics | |
|---|---|
| Market cap | US$2.76k |
| Earnings (TTM) | -US$2.57m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs FPMI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FPMI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$2.57m |
| Earnings | -US$2.57m |
Last Reported Earnings
Dec 31, 2016
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did FPMI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/08 16:04 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2016/12/31 |
| Annual Earnings | 2016/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
FluoroPharma Medical, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Juan Noble | Taglich Brothers, Inc. |
| Brian Marckx | Zacks Investment Research Inc. |